Component
Human vaccinia-related kinase 1 / VRK1
Context-specific entity; species, compartment and exposure are stated on each claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Pull-down, SPR and NMR experiments supported direct luteolin binding near the human VRK1 catalytic domain.
Experimental context and source evidence
- evidence_access
- Primary full text
- experimental_model
- Recombinant protein and human-cell lysates.
- limitations
- No crystal-defined pose; published SPR table constants are not used here as a validated affinity.
- nutrient_topic
- Luteolin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Luteolin / 3′,4′,5,7-tetrahydroxyflavone
- plain_language
- Physical binding evidence accompanies the kinase result.
- primary_references
- Luteolin suppresses cancer cell proliferation by targeting vaccinia-related kinase 1. · 2014 · https://pubmed.ncbi.nlm.nih.gov/25310002/ · DOI 10.1371/journal.pone.0109655
Luteolin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 348–354
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Recombinant protein and human-cell lysates. · source_derived_draft · unverified_draft
## luteolin-vrk1-binding Physical binding evidence accompanies the kinase result. Pull-down, SPR and NMR experiments supported direct luteolin binding near the human VRK1 catalytic domain. Model: Recombinant protein and human-cell lysates. Limitations: No crystal-defined pose; published SPR table constants are not used here as a validated affinity. Evidence access: Primary full text Luteolin suppresses cancer cell proliferation by targeting vaccinia-related kinase 1. · 2014 · https://pubmed.ncbi.nlm.nih.gov/25310002/ · DOI 10.1371/journal.pone.0109655
Complete structured claim and evidence
Where it participates (unsigned role)
Luteolin reduced VRK1-mediated BAF phosphorylation; 10 micromolar treatment altered nuclear morphology in HeLa cells.
Experimental context and source evidence
- evidence_access
- Primary full text
- experimental_model
- Recombinant kinase and human HeLa-cell experiments.
- limitations
- Not a selective VRK1 inhibitor or a demonstrated cancer therapy.
- nutrient_topic
- Luteolin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Luteolin / 3′,4′,5,7-tetrahydroxyflavone
- plain_language
- Kinase inhibition changed a nuclear-envelope regulator.
- primary_references
- Luteolin suppresses cancer cell proliferation by targeting vaccinia-related kinase 1. · 2014 · https://pubmed.ncbi.nlm.nih.gov/25310002/ · DOI 10.1371/journal.pone.0109655
Luteolin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 356–362
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Recombinant kinase and human HeLa-cell experiments. · source_derived_draft · unverified_draft
## luteolin-vrk1-baf Kinase inhibition changed a nuclear-envelope regulator. Luteolin reduced VRK1-mediated BAF phosphorylation; 10 micromolar treatment altered nuclear morphology in HeLa cells. Model: Recombinant kinase and human HeLa-cell experiments. Limitations: Not a selective VRK1 inhibitor or a demonstrated cancer therapy. Evidence access: Primary full text Luteolin suppresses cancer cell proliferation by targeting vaccinia-related kinase 1. · 2014 · https://pubmed.ncbi.nlm.nih.gov/25310002/ · DOI 10.1371/journal.pone.0109655
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.